Virbac (CHIX:VIRPP) Moat Score: 7/10 (As of Jul. 07, 2026)


CHIX:VIRPP Virbac SA CHIX:VIRPP
95 GF Score
Price €334.00
GF Value €350.14
! 2 Warning Signs
View Full Analysis

What is Virbac Moat Score?

Virbac CHIX:VIRPP 95 Moat Score is 7 as of Jul. 07, 2026. GuruFocus rates CHIX:VIRPP with a GF Score™ of 95/100 and a GF Value™ of €350.14. The stock has 2 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Virbac ranks better than 98.64% on this metric.

Virbac has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Virbac has Virbac SA has a narrow moat with strong brand recognition and customer loyalty in the animal health industry. It benefits from a robust distribution network, regulatory barriers, and some pricing power. However, competition and limited cost advantages constrain its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Virbac might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Virbac  (CHIX:VIRPp) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Virbac Moat Score Related Terms

CHIX:VIRPP vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Virbac's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virbac Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's Moat Score distribution charts can be found below:

* The bar in red indicates where Virbac's Moat Score falls into.


CHIX:VIRPP
95GF Score
Virbac SA CHIX:VIRPP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Virbac (CHIX:VIRPP) has a Moat Score of 7 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Virbac ranks #14 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Virbac's Moat Score too high?
Virbac's current Moat Score is 7. Based on the distribution chart, Virbac ranks #14 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Virbac has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #14 out of 1032 companies for Moat Score. This places Virbac in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Virbac's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current Moat Score of 7. The stock's GF Value™ is €350.14, compared to a current price of €334.00 — trading 4.6% below its estimated fair value. The current Moat Score is 7. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Moat Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €334.00 is trading 4.6% below its estimated GF Value™ of €350.14.

Key valuation signals for CHIX:VIRPP:

  • Moat Score: 7
  • GF Value™: €350.14 vs. price of €334.00 (4.6% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score

Get the complete analysis for CHIX:VIRPP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€334.00
Price
€350.14
GF Value